ESMO 2023: Will J&J’s Rybrevant Be Able To Scale The Tagrisso Mountain?

Scrip talked to Johnson & Johnson’s vice president of oncology global medical affairs, Mark Wildgust, about how the healthcare giant hopes to plant a flag on Tagrisso’s mountain with its trio of Phase III butterfly-themed studies for the bispecific antibody Rybrevant presented at ESMO.